Access to troriluzole for spinocerebellar ataxia
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial provides access to an unapproved medication called troriluzole for people with spinocerebellar ataxia (SCA), a rare condition that affects coordination and movement. The drug may help slow progression, and this program offers a chance to receive it before it's widely available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of spinocerebellar ataxia (SCA) — either through genetic testing or by clinical signs.
- Your liver function must be adequate (no serious liver disease).
- You must not have any serious medical condition that could interfere with the treatment or increase your risk.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a non-invasive brain stimulation treatment (called cerebellar transcranial magnetic stimulation) can help improve balance and coordination in people with spinocerebellar ataxia. It may offer a new way to ease symptoms without surgery.
This trial tests an experimental stem cell treatment for people with SCA3, a genetic condition that affects balance and coordination. The goal is to see if the treatment can help improve or slow down these symptoms.
This study tests whether cycling-based coordination training can help people with spinocerebellar ataxia (SCA) improve balance and movement by priming the brain for recovery.
This trial studies whether riluzole can help people with spinocerebellar ataxia type 7 (SCA7), a genetic condition that affects balance and coordination. It may help slow symptoms or improve daily function, and you’d be closely monitored for side effects.
This early-phase study tests whether VO659 is safe and how the body processes it in people with certain genetic movement disorders (SCA1, SCA3, or Huntington disease). It may help researchers learn the right dose and whether the drug can be given safely.
This trial tests a non-invasive brain stimulation method to see if it can improve movement and balance in people with spinocerebellar ataxia type 3. It aims to find the best settings for this treatment.
Hear when a new SCA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.